Who Should NOT Consider Peptides Based on current evidence, I would advise against peptide use in the following individuals: Anyone with a current or recent cancer diagnosis Anyone with a strong family history of hormone-sensitive cancers (breast, ovarian, uterine, prostate, colorectal) Anyone with genetic mutations predisposing to cancer (BRCA1/2, Lynch syndrome, etc.) Anyone with active autoimmune disease or severe inflammatory conditions Pregnant or breastfeeding women Anyone who has not established foundational health practices Competitive athletes (most peptides are banned substances) Anyone seeking a "quick fix" rather than commitment to comprehensive health optimization If Considering Peptides: A Cautious Approach For patients who have established solid foundations, have no contraindications, understand the limitations of current evidence, and wish to explore peptides as a potential adjunct, here is the approach I might considerwith significant caveats: Lower-Risk Starting Point Topical GHK-Cu: This has the most established safety profile and documented benefits for skin health
Weight loss can sometimes lead to changes in vitamin D levels
Most of the analytic work in this study was performed on an LCMS system that represents a powerful tool in identifying and characterizing xenobiotic metabolites (Oliveira and Watson 2000)
Although IGF-IR promotes EMT, it does not necessarily mean that inhibition of IGF-IR is able to reverse this phenotype, due to the compensation by other RTKs
Although real-world flexibility can benefit some patients, it should not replace evidence-based protocols entirely
(MASLD)
